Peptides & HGH

Desira Pen Bremelanotide PT-141 20 mg SunSci Pharmaceutical

SunSci Pharmaceutical

85,00

In Stock (100 available)

Desira Pen Bremelanotide PT-141 20 mg SunSci Pharmaceutical (20 mg) — Backed by SunSci Pharmaceutical’s commitment to quality, a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that …

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Desira Pen Bremelanotide PT-141 20 mg SunSci Pharmaceutical — Backed by a rigorous commitment to quality, a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that produces skin darkening (tanning) without UV exposure. It also has notable effects on libido enhancement and appetite suppression. PT-141 (Bremelanotide) is a derivative focused specifically on sexual function enhancement. This formulation is dosed at 20 mg per pre-filled pen.

Key Benefits

  • Synthetic melanocortin agonist — MC3/MC4R selective
  • On-demand libido enhancement without cardiovascular effect
  • Subcutaneous injection 45 minutes before desired effect
  • Approved (Vyleesi) for female hypoactive sexual desire disorder
  • Off-label male use for sexual function enhancement
  • Each unit dosed at 20 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Clinical dosing: 1.75 mg SubQ 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours, 8 doses per month. Research/male protocols: 1–2 mg SubQ as needed.

How It Works

Synthetic cyclic peptide, MC3/MC4 receptor agonist. Acts centrally on brain melanocortin pathways to enhance libido and sexual response. Distinct from PDE5 inhibitors (Viagra/Cialis) which act peripherally on vasodilation.

Pharmacokinetics

Plasma half-life approximately 2.7 hours. Effect onset 45 minutes post-injection, duration 6–10 hours. Reconstituted vial stable in fridge 6 weeks.

Potential Side Effects

Transient blood-pressure elevation (monitor if hypertensive). Nausea in 40% of first-time users. Facial flushing. Skin hyperpigmentation with repeated dosing — MC1R activation side-effect.

Cycle & Stacking Guide

On-demand use; not a scheduled protocol. Stacks with PDE5 inhibitors if erectile function is also a concern (different mechanisms, additive effect). Not for daily use.

Manufacturer Notes

SunSci Pharmaceutical produces semaglutide pens and growth hormone products. Cold-chain shipping for all biological products.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Desira Pen Bremelanotide PT-141 20 mg SunSci Pharmaceutical”

Your email address will not be published. Required fields are marked *

Bremelanotide

Physical & Chemical Properties for Research Purposes
Chemical structure of Bremelanotide (C50H68N14O10) for laboratory analysis
2D structural representation · PubChem CID 9941379 ↗
Chemical Identity
# CAS Registry Number 189691-06-3
Σ IUPAC Name Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (cyclic lactam heptapeptide)
F Molecular Formula C50H68N14O10
M Molecular Weight 1025.17 g/mol
Melting Point N/A (peptide) °C
Solubility Soluble in water
Biological Half-life 2.7 hours (SC)
PubChem CID 9941379 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity None
Known trade names: PT-141, Vyleesi

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.